Systemic amyloidoses are potentially lethal ... amyloidosis and intensive chemotherapy in immunoglobulin light chain (AL) amyloidosis. These therapies often elicit substantial morbidity and ...

This important study identifies the "H-state" as a potential conformational marker distinguishing amyloidogenic from non-amyloidogenic light chains, addressing a critical problem in protein misfolding ...

Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis, Johnson & Johnson’s Darzalex has been given the go-ahead for ...

Preclinical studies have shown AT-02 is able to bind to multiple amyloid types and can induce macrophage mediated amyloid phagocytosis and removal. The Food and Drug Administration has granted Orphan ...

In a review article of AL amyloidosis "Systemic Light Chain Amyloidosis," Vaishali Sanchorawala, MD, director of the ...

The leading AL Amyloidosis Companies such as Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, ZENTALIS ...

As a result, the company expects AT-02 to bind specifically to amyloid in systemic amyloidosis patients ... Phase 1 trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis patients.

Different types of systemic amyloidosis are recognized depending ... amyloid A amyloidosis (AA), immunoglobulin light chain amyloidosis (AL) and transthyretin-related amyloidosis (ATTR).

The investigational treatment is currently being evaluated in a 3-part phase 1 trial (ClinicalTrials.gov Identifier: NCT05521022) in adult patients with systemic amyloidosis, as well as a phase 2 ...